Combined treatment with statin and angiotensin-receptor blocker after stenting as a useful strategy for prevention of coronary restenosis

Journal of Cardiology

Volumn 45, Issue 3, 2005, Pages 107-113

  Nishikawa, Hiroaki ^a   Miura, Shin Ichiro ^a   Shimomura, Hideki ^b   Tsujita, Kenichi ^b   Okamura, Keisuke ^a   Zhang, Bo ^a   Iwata, Atsushi ^a   Shirai, Kazuyuki ^a   Matsuo, Kunihiro ^a   Arai, Hidekazu ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fukuoka Tokushukai Hospital   (Japan)

Author keywords

Angiotensin II (angiotensin II receptor blocker); Cardiovascular disease; Cholesterol lowering drugs (statin); Restenosis; Stent

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CANDESARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOSARTAN; PRAVASTATIN; STATINE DERIVATIVE; TICLOPIDINE; VALSARTAN; ANGIOTENSIN RECEPTOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; RESTENOSIS; RISK ASSESSMENT; STENT; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; MOUSE; RISK;

AGED; ANGINA PECTORIS; ANIMALS; CASE-CONTROL STUDIES; CORONARY DISEASE; CORONARY RESTENOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MIDDLE AGED; ODDS RATIO; RECEPTORS, ANGIOTENSIN; STENTS;

EID: 19944370119     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kastelein JJ: The future of best practice. Atherosclerosis 1999; 143(Suppl 1): S17-S21
2. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307
5. Mulder HJ, Bal ET, Jukema JW, Zwinderman AH, Schalij MJ, van Boven AJ, Bruschke AV: Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 2000; 86: 742-746
6. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Poster PJ: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographie restenosis (FLARE) trial. Eur Heart J 1999; 20: 58-69
7. Walter DH, Fichtischerer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, Zeiher AM: Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38: 2006-2012
8. Fogari R, De Gasparo M: Addressing those two that go together: The angiotensin II receptors and their role in blood-flow regulation. Blood Press 2001; 10: 6-15
9. Prescott MF, Webb RL, Reidy MA: Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist: Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol 1991; 139: 1291-1296
10. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A: Valsartan for the prevention of restenosis after stenting of typeB2/C lesions: The Val-PREST trial. J Inv Cardiol 2001; 13: 93-97
11. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-112
12. Kay IP, Sabate M, Van Langenhove G, Heyndrickx GR, Grollier G, Suyrapranata H, Hoorntje JC, van der Giessen WJ, Morel MA, Disco C, Serruys PW: The ESSEX (European Scimed Stent Experience) study. Cathet Cardiovasc Intervent 2000; 50: 419-425
13. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696
14. Saku K, Zhang B, Ohta T, Arakawa K: Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999; 33: 436-443
15. Yu ZX, Tamai H, Kyo E, Kosuga K, Hata T, Okada M, Nakamura T, Komori H, Tsuji T, Takeda S, Motohara S, Uehata H: Comparison of the self-expanding Radius stent and the balloon-expandable Multilink stent for elective treatment of coronary stenoses: A serial analysis by intravascular ultrasound. Cathet Cardiovasc Intervent 2002; 56: 40-45
16. Kobayashi Y, Honda Y, Christie GL, Teirstein PS. Bailey SR, Brown CL III, Matthews RV, De Franco AC, Schwartz RS, Goldberg S, Popma JJ, Yock PG, Fitzgerald PJ: Long-term vessel response to a self-expanding coronary stent: A serial volumetric intravascular ultrasound analysis from the ASSURE Trial: A Stent vs. Stent Ultrasound Remodeling Evaluation. J Am Coll Cardiol 2001; 37: 1329-1334
17. Wilson DP, Saward L, Zahradka P, Cheung PK: Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 1999; 42: 761-772
18. Kim S. Ohta K, Hamaguchi A. Omura T, Yukimura T, Miura K, Inada Y, Ishimura Y, Chatani F, Iwao H: Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995; 273: 509-515
19. Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, Bohm M, Nickenig G: Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin ATI receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646-654
20. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, Kikuchi K: Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999; 376: 139-148